Literature DB >> 14678954

Gastric inhibitory polypeptide does not inhibit gastric emptying in humans.

Juris J Meier1, Oliver Goetze, Jens Anstipp, Dirk Hagemann, Jens J Holst, Wolfgang E Schmidt, Baptist Gallwitz, Michael A Nauck.   

Abstract

The insulinotropic gut hormone gastric inhibitory polypeptide (GIP) has been demonstrated to inhibit gastric acid secretion and was proposed to possess "enterogastrone" activity. GIP effects on gastric emptying have not yet been studied. Fifteen healthy male volunteers (23.9 +/- 3.3 yr, body mass index 23.7 +/- 2.3 kg/m(2)) were studied with the intravenous infusion of GIP (2 pmol.kg(-1).min(-1)) or placebo, each administered to the volunteers on separate occasions from -30 to 360 min in the fasting state. At 0 min, a solid test meal (250 kcal containing [(13)C]sodium octanoate) was served. Gastric emptying was calculated from the (13)CO(2) exhalation rates in breath samples collected over 360 min. Venous blood was drawn in 30-min intervals for the determination of glucose, insulin, C-peptide, and GIP (total and intact). Statistical calculations were made by use of repeated-measures ANOVA and one-way ANOVA. During the infusion, GIP rose to steady-state concentrations of 159 +/- 15 pmol/l for total and 34 +/- 4 pmol/l for intact GIP (P < 0.0001). Meal ingestion further increased GIP concentrations in both groups, reaching peak levels of 265 +/- 20 and 82 +/- 9 pmol/l for total and 67 +/- 7 and 31 +/- 9 pmol/l for intact GIP during the administration of GIP and placebo, respectively (P < 0.0001). There were no differences in glucose, insulin, and C-peptide between the experiments with the infusion of GIP or placebo. Gastric half-emptying times were 120 +/- 9 and 120 +/- 18 min (P = 1.0, with GIP and placebo, respectively). The time pattern of gastric emptying was similar in the two groups (P = 0.98). Endogenous GIP secretion, as derived from the incremental area under the curve of plasma GIP concentrations in the placebo experiments, did not correlate to gastric half-emptying times (r(2) = 0.15, P = 0.15 for intact GIP; r(2) = 0.21, P = 0.086 for total GIP). We conclude that gastric emptying does not appear to be influenced by GIP. The secretion of GIP after meal ingestion is not suppressed by its exogenous administration. The lack of effect of GIP on gastric emptying underlines the differences between GIP and the second incretin glucagon-like peptide 1.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14678954     DOI: 10.1152/ajpendo.00499.2003

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  27 in total

1.  Xenin-25 potentiates glucose-dependent insulinotropic polypeptide action via a novel cholinergic relay mechanism.

Authors:  Burton M Wice; Songyan Wang; Dan L Crimmins; Kelly A Diggs-Andrews; Matthew C Althage; Eric L Ford; Hung Tran; Matthew Ohlendorf; Terry A Griest; Qiuling Wang; Simon J Fisher; Jack H Ladenson; Kenneth S Polonsky
Journal:  J Biol Chem       Date:  2010-04-26       Impact factor: 5.157

Review 2.  Peripheral neural targets in obesity.

Authors:  Amanda J Page; Erin Symonds; Madusha Peiris; L Ashley Blackshaw; Richard L Young
Journal:  Br J Pharmacol       Date:  2012-07       Impact factor: 8.739

3.  Impact of cereal fibre on glucose-regulating factors.

Authors:  M O Weickert; M Mohlig; C Koebnick; J J Holst; P Namsolleck; M Ristow; M Osterhoff; H Rochlitz; N Rudovich; J Spranger; A F H Pfeiffer
Journal:  Diabetologia       Date:  2005-09-20       Impact factor: 10.122

Review 4.  Relationship Between Control of Glycemia and Gastric Emptying Disturbances in Diabetes Mellitus.

Authors:  Magnus Halland; Adil E Bharucha
Journal:  Clin Gastroenterol Hepatol       Date:  2015-12-21       Impact factor: 11.382

5.  Influence of gastric inhibitory polypeptide on pentagastrin-stimulated gastric acid secretion in patients with type 2 diabetes and healthy controls.

Authors:  Juris J Meier; Michael A Nauck; Bartholomaeus Kask; Jens J Holst; Carolyn F Deacon; Wolfgang E Schmidt; Baptist Gallwitz
Journal:  World J Gastroenterol       Date:  2006-03-28       Impact factor: 5.742

6.  Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans.

Authors:  J Schirra; M Nicolaus; R Roggel; M Katschinski; M Storr; H J Woerle; B Göke
Journal:  Gut       Date:  2005-06-28       Impact factor: 23.059

Review 7.  The role of incretins in glucose homeostasis and diabetes treatment.

Authors:  Wook Kim; Josephine M Egan
Journal:  Pharmacol Rev       Date:  2008-12-12       Impact factor: 25.468

8.  Esophageal and Gastric Dysmotilities are Associated with Altered Glucose Homeostasis and Plasma Levels of Incretins and Leptin.

Authors:  Rebecka Hammersjö; Bodil Roth; Peter Höglund; Bodil Ohlsson
Journal:  Rev Diabet Stud       Date:  2016-05-10

9.  The effect of dipeptidyl peptidase-4 inhibition on gastric volume, satiation and enteroendocrine secretion in type 2 diabetes: a double-blind, placebo-controlled crossover study.

Authors:  Adrian Vella; Gerlies Bock; Paula D Giesler; Duane B Burton; Denise B Serra; Monica Ligueros Saylan; Carolyn F Deacon; James E Foley; Robert A Rizza; Michael Camilleri
Journal:  Clin Endocrinol (Oxf)       Date:  2008-03-10       Impact factor: 3.478

10.  Exogenous glucose-dependent insulinotropic polypeptide worsens post prandial hyperglycemia in type 2 diabetes.

Authors:  Chee W Chia; Olga D Carlson; Wook Kim; Yu-Kyong Shin; Cornelia P Charles; Hee Seung Kim; Denise L Melvin; Josephine M Egan
Journal:  Diabetes       Date:  2009-03-10       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.